NHS And Sandoz Look Into Natalizumab Switching Reports
Media Reports Indicate Adverse Reactions From Patients At A UK Hospital
The UK’s NHS and Sandoz have both told Generics Bulletin that they are looking into reports from a single UK hospital of adverse reactions linked to patients that have switched from Tysabri to Sandoz’s Tyruko biosimilar.
